![Gerszten-Robert.png](https://static.wixstatic.com/media/039d63_f1fcef0ffdce4d75bfcfe3a7079b86eb~mv2.png/v1/crop/x_0,y_0,w_2400,h_2694/fill/w_400,h_449,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Gerszten-Robert.png)
Dr. Robert Gerszten
Chief of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston
Herman Dana Professor of Medicine at Harvard Medical School
Senior Associate Member of the Broad Institute
​
Dr. Robert Gerszten serves as a member of the APC Council. His term runs from 2022 through 2024.
•••
Dr. Gerszten’s investigations focus on the nexus of cardiac and metabolic diseases. His translational research program leverages metabolomics and proteomics technologies for the discovery of new biomarkers and pathways contributing to atherogenesis and its complications. His highly collaborative program extends across a spectrum of institutions, from the Broad Institute to the Framingham Heart Study, the Jackson Heart Study, the Diabetes Prevention Program, and the Thrombolysis in Myocardial Infarction (TIMI) Study Group. His work has been funded by the U.S. National Institutes of Health and the American Heart Association, from whom he received an Established Investigator Award. Dr. Gerszten is a member of the American Society for Clinical Investigation, the Association of American Physicians, and the Association of University Cardiologists. He is a recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School.
Education and Training
-
Johns Hopkins School of Medicine
-
Residency, University of Pennsylvania
-
Clinical Fellowship, Cardiology at Massachusetts General Hospital
-
Research Fellowship, Cardiovascular Research Institute, University of California, San Francisco
-
Research Fellowship, Cardiovascular Research Center, Massachusetts General Hospital